Olivier Molinier
A5077305357- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- Occupational and environmental lung diseases
- Colorectal Cancer Treatments and Studies
- Pleural and Pulmonary Diseases
- Neuroendocrine Tumor Research Advances
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Asthma and respiratory diseases
- Brain Metastases and Treatment
- Cancer therapeutics and mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Multiple and Secondary Primary Cancers
- Obstructive Sleep Apnea Research
- Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Medical Imaging and Pathology Studies
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
Centre Hospitalier du Mans
2015-2024
Intergroupe Francophone de Cancérologie Thoracique
2015-2023
Centre Hospitalier Annecy Genevois
2020
Nantes Université
2019
Inserm
2019
Centre Hospitalier d'Angoulême
2019
Canadian Respiratory Research Network
2016
University Medical Center Hamburg-Eppendorf
2013
Heidelberg University
2013
University Hospital Heidelberg
2013
Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0.49 to 0.79; P < .001). Here we report final overall survival (OS) and updated safety data. Patients Methods all, 939 patients with advanced nonsquamous non–small-cell lung cancer (NSCLC) received four cycles pemetrexed-cisplatin induction therapy; then, 539 no Eastern Cooperative Oncology Group performance status 0 or...
The use of web-based monitoring for lung cancer patients is growing in interest because promising recent results suggesting improvement and resource utilization outcomes. It remains an open question whether the overall survival (OS) these could be improved by using a web-mediated follow-up rather than classical scheduled imaging.Advanced-stage without evidence disease progression after or during initial treatment were randomly assigned multicenter phase III trial to compare algorithm...
PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non–small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 50% without actionable driver mutations. It not known whether adding ipilimumab to pembrolizumab improves efficacy over alone in this population. METHODS In the randomized, double-blind, phase III KEYNOTE-598 trial (ClinicalTrials.gov identifier: NCT03302234 ), eligible patients previously untreated NSCLC...
IntroductionTo offer patients with EGFR mutation–positive advanced NSCLC appropriate tyrosine kinase inhibitor treatment, mutation testing of tumor samples is required. However, tissue/cytologic are not always available or evaluable. The large, noninterventional diagnostic ASSESS study (NCT01785888) evaluated the utility circulating free tumor-derived DNA (ctDNA) from plasma for testing.MethodsASSESS was conducted in 56 centers (in Europe and Japan). Eligible (with newly diagnosed locally...
Background The IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant durvalumab, for early-stage resectable non-small-cell lung cancer (NSCLC). Methods In a multicenter, single-arm, phase II trial, patients with IB (≥4 cm)-IIIA, non-N2, NSCLC received three doses durvalumab (750 mg every 2 weeks) and underwent surgery between 14 days after last infusion. primary endpoint was complete surgical resection rate. Secondary endpoints included tumor response rate, major...
Long-term changes in lung cancer (LC) patients are difficult to evaluate. We report results from the French KBP-2020 real-life cohort.KBP-2020 was a prospective cohort that included all diagnosed with LC 2020, nonacademic public hospital France. Patient and tumour characteristics were described compared similarly designed cohorts 2000 2010.In 82 centers 8,999 LC. The proportion of women increased: 34·6% (3114/8999) to, 24·3% (1711/7051) 16·0% (904/5667) 2010 (p<0·0001). non-smokers higher...
Despite advances in cancer therapy, mortality is still high except early-stage tumors, and screening remains a challenge. The randomized National Lung Screening Trial (NLST), comparing annual low-dose computed tomography (LDCT) chest X-rays, revealed 20% decrease lung-cancer-specific mortality. These results raised numerous questions. French intergroup for thoracic oncology the French-speaking group convened an expert to provide coherent outlook on modalities France.A literature review was...